216 related articles for article (PubMed ID: 38484745)
21. Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.
Cupp E; Sauerbrey M; Cama V; Eberhard M; Lammie PJ; Unnasch TR
Infect Dis Poverty; 2019 Jul; 8(1):50. PubMed ID: 31303176
[TBL] [Abstract][Full Text] [Related]
22. Contribution and performance of female Community-Directed Distributors in the treatment of onchocerciasis with Ivermectin in Sub-Saharan Africa: a systematic review.
Vouking MZ; Tamo VC; Tadenfok CN
Pan Afr Med J; 2015; 20():188. PubMed ID: 26430485
[TBL] [Abstract][Full Text] [Related]
23. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
Turner HC; Walker M; Attah SK; Opoku NO; Awadzi K; Kuesel AC; Basáñez MG
Parasit Vectors; 2015 Mar; 8():167. PubMed ID: 25889256
[TBL] [Abstract][Full Text] [Related]
24. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes.
Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
Infect Dis Poverty; 2018 Jul; 7(1):63. PubMed ID: 29966535
[TBL] [Abstract][Full Text] [Related]
25. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
[TBL] [Abstract][Full Text] [Related]
26. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
[TBL] [Abstract][Full Text] [Related]
27. Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance.
Guevara Á; Lovato R; Proaño R; Rodriguez-Perez MA; Unnasch T; Cooper PJ; Guderian RH
Parasit Vectors; 2018 Apr; 11(1):265. PubMed ID: 29690907
[TBL] [Abstract][Full Text] [Related]
28. The Onchocerciasis Elimination Program for the Americas (OEPA).
Sauerbrey M
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
[TBL] [Abstract][Full Text] [Related]
29. Impact of combined large-scale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea.
Guillet P; Sékétéli A; Alley ES; Agoua H; Boatin BA; Bissan Y; Akpoboua LK; Quillévéré D; Samba EM
Bull World Health Organ; 1995; 73(2):199-205. PubMed ID: 7743591
[TBL] [Abstract][Full Text] [Related]
30. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.
Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH
BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085
[TBL] [Abstract][Full Text] [Related]
32. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
33. Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration.
Efon-Ekangouo A; Nana-Djeunga HC; Nzune-Toche N; Dongmo-Yemele R; Bopda J; Ongbassomben V; Sumo L; Geiger A; Nutman TB; Kamgno J
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011250. PubMed ID: 37058547
[TBL] [Abstract][Full Text] [Related]
34. Effect of onchocerciasis elimination measures on the incidence of epilepsy in Maridi, South Sudan: a 3-year longitudinal, prospective, population-based study.
Jada SR; Amaral LJ; Lakwo T; Carter JY; Rovarini J; Bol YY; Logora MY; Hadermann A; Hopkins A; Fodjo JNS; Colebunders R
Lancet Glob Health; 2023 Aug; 11(8):e1260-e1268. PubMed ID: 37474232
[TBL] [Abstract][Full Text] [Related]
35. Progress towards elimination of onchocerciasis in the Region du Sud-Ouest of Burkina Faso which was previously subject to a recrudescence event after vector control.
Nikièma AS; Koala L; Post RJ; Kima A; Compaoré J; Kafando CM; Nana JB; Bougouma C; Faye B; Traoré S; Dabiré RK
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012118. PubMed ID: 38683750
[TBL] [Abstract][Full Text] [Related]
36. Genome-based tools for onchocerciasis elimination: utility of the mitochondrial genome for delineating Onchocerca volvulus transmission zones.
Crawford KE; Hedtke SM; Doyle SR; Kuesel AC; Armoo S; Osei-Atweneboana MY; Grant WN
Int J Parasitol; 2024 Mar; 54(3-4):171-183. PubMed ID: 37993016
[TBL] [Abstract][Full Text] [Related]
37. Population biology of human onchocerciasis.
Basáñez MG; Boussinesq M
Philos Trans R Soc Lond B Biol Sci; 1999 Apr; 354(1384):809-26. PubMed ID: 10365406
[TBL] [Abstract][Full Text] [Related]
38. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.
Tekle AH; Zouré HG; Noma M; Boussinesq M; Coffeng LE; Stolk WA; Remme JH
Infect Dis Poverty; 2016 Jun; 5(1):66. PubMed ID: 27349645
[TBL] [Abstract][Full Text] [Related]
39. Progress towards onchocerciasis elimination in Côte d'Ivoire: A geospatial modelling study.
Eneanya OA; Koudou BG; Aboulaye M; Elvis AA; Souleymane Y; Kouakou MM; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009091. PubMed ID: 33566805
[TBL] [Abstract][Full Text] [Related]
40. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?
Frempong KK; Walker M; Cheke RA; Tetevi EJ; Gyan ET; Owusu EO; Wilson MD; Boakye DA; Taylor MJ; Biritwum NK; Osei-Atweneboana M; Basáñez MG
Clin Infect Dis; 2016 Jun; 62(11):1338-1347. PubMed ID: 27001801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
